ClinicalTrials.gg

Program

umeclidinium bromide

Also written as “Budesonide, Formoterol Fumarate, and Umeclidinium Bromide”, “Umeclidinium bromide 62.5mcg” and “Umeclidinium bromide 125mcg”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by 2 companies.

Furthest: phase 4, since Apr 15, 20247 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline61 open or runningphase 4since Apr 15, 2024Jan 17, 2013none ahead
Chenpon Pharmaceutical10 open or runningphase 2since Aug 31, 2026Aug 31, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 17, 2013First studies: 2 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNew to GlaxoSmithKlineGlaxoSmithKline · NCT01772147, NCT01772134
  2. Mar 28, 2013Phase 3 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT01822899 · 717 enrolled · Czechia, Denmark, Germany and more
  3. Jun 12, 2014Phase 3 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02164513 · 10,355 enrolled · United States, Argentina, Australia and more
  4. Jul 3, 2014Phase 3 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02184611 · 308 enrolled · China, Korea, Republic of
  5. Apr 15, 2024Phase 4 study in AsthmaGlaxoSmithKline · NCT06372496 · 1,358 enrolled · United States, Argentina, Australia and more
  6. Aug 31, 2026Chenpon Pharmaceutical's first study: phase 2 study in AsthmaNew to Chenpon PharmaceuticalChenpon Pharmaceutical · NCT07807007 · 150 enrolled · China

TargetBeta

CHRM3 →read by rule
“Muscarinic acetylcholine receptor M3 antagonist”ChEMBL 37, by rule

Other programs on CHRM3

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
trospiumruleBristol-Myers Squibbphase 421
trospium chlorideruleBristol-Myers Squibbphase 415
AtropineruleLaboratorios Sophia S.A de C.V.phase 317
TQC3927Sino Biopharmaceuticalphase 23
TQC3302Sino Biopharmaceuticalphase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07807007Asthma · China2CompletedChenpon PharmaceuticalAug 3, 2026150
NCT06372496Asthma · United States, Argentina, Australia and more4Active, not recruitingGlaxoSmithKlineJul 28, 20251,358
NCT02184611Pulmonary Disease, Chronic Obstructive · China, Korea, Republic of3CompletedGlaxoSmithKlineNov 8, 2017308
NCT02164513Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineJul 17, 201710,355
NCT01822899Pulmonary Disease, Chronic Obstructive · Czechia, Denmark, Germany and more3CompletedGlaxoSmithKlineOct 1, 2013717
NCT01772147Pulmonary Disease, Chronic Obstructive · United States, Chile, Czech Republic and more3CompletedGlaxoSmithKlineAug 2013608
NCT01772134Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more3CompletedGlaxoSmithKlineJul 1, 2013617

How it is read

Names in the registry

  • “Budesonide, Formoterol Fumarate, and Umeclidinium Bromide”, 2 entries
  • “Umeclidinium bromide 62.5mcg”, 2 entries
  • “Umeclidinium bromide 125mcg”, 2 entries
  • “Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate”, 1 entry
  • “Umeclidinium bromide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.